Latest Regulatory News

CD Private Equity Fund II has announced a special unfranked dividend of AUD 0.09 per ordinary unit, payable on February 24, 2025, signaling steady returns for investors.

Biome Australia Limited has expanded its distribution footprint to over 6,000 health retail and practitioner locations, marking a 20% increase in six months and advancing toward its Vision 27 target of 8,000 sites by FY27.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

Tower Limited has appointed CFO Paul Johnston as interim CEO following Blair Turnbull's resignation, with Deputy CFO Angus Shelton stepping in as interim CFO pending regulatory approval.

Stavely Minerals has reported significant progress in its copper and nickel exploration projects, highlighting promising assay results and new structural insights that could unlock major resource expansions.

Peregrine Gold Limited has updated its prospectus to reveal a significant increase in share commitments from its largest shareholder, Yandal Investments, alongside key directors’ participation in the capital raise.

Australian Rare Earths Limited has secured a $5 million government grant to advance its Koppamurra Rare Earths Project, while initial drilling at its Overland Uranium Project validates promising geological models for uranium deposits.

Neometals Ltd has bolstered its financial position with a A$7.1 million capital raise while progressing key projects including the commissioning of a lithium-ion battery recycling plant in Germany and preparing for maiden gold drilling at Barrambie.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Cardiex Limited has commenced U.S. deliveries of its CONNEQT Pulse arterial health monitor alongside the launch of its companion CONNEQT App, marking a pivotal expansion into the American digital health market.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.